Immune Responses Regulated by Cannabidiol.
James M. Nichols,Barbara L. F. Kaplan +1 more
- 27 Feb 2020
- Vol. 5, Iss: 1, pp 12-31
229
TL;DR: Overall, the data overwhelmingly support the notion that CBD is immune suppressive and that the mechanisms involve direct suppression of activation of various immune cell types, induction of apoptosis, and promotion of regulatory cells, which, in turn, control other immune cell targets.
read more
Abstract: Introduction: Cannabidiol (CBD) as Epidiolex® (GW Pharmaceuticals) was recently approved by the U.S. Food and Drug Administration (FDA) to treat rare forms of epilepsy in patients 2 years of age and older. Together with the increased societal acceptance of recreational cannabis and CBD oil for putative medical use in many states, the exposure to CBD is increasing, even though all of its biological effects are not understood. Once such example is the ability of CBD to be anti-inflammatory and immune suppressive, so the purpose of this review is to summarize effects and mechanisms of CBD in the immune system. It includes a consideration of reports identifying receptors through which CBD acts, since the "CBD receptor," if a single one exists, has not been definitively identified for the myriad immune system effects. The review then provides a summary of in vivo and in vitro effects in the immune system, in autoimmune models, with a focus on experimental autoimmune encephalomyelitis, and ends with identification of knowledge gaps. Conclusion: Overall, the data overwhelmingly support the notion that CBD is immune suppressive and that the mechanisms involve direct suppression of activation of various immune cell types, induction of apoptosis, and promotion of regulatory cells, which, in turn, control other immune cell targets.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test.
Ila M. P. Linares,Antonio Waldo Zuardi,Antonio Waldo Zuardi,Luis C Pereira,Regina Helena Costa Queiroz,Raphael Mechoulam,Francisco S Guimarães,José Alexandre de Souza Crippa,José Alexandre de Souza Crippa +8 more
TL;DR: Findings confirm the anxiolytic-like properties of CBD and are consonant with results of animal studies describing bell-shaped dose-response curves, and Optimal therapeutic doses of CBD should be rigorously determined.
209
Cannabidiol: pharmacology and therapeutic targets
TL;DR: The molecular targets, pharmacokinetics, and safety and abuse liability of CBD are reviewed; additionally, the extant evidence on its potential therapeutic effects for neurological disorders, pain, inflammation, conditions related to immune function, psychiatric disorders, and substance use are described.
204
Industrial Hemp ( Cannabis sativa subsp. sativa ) as an Emerging Source for Value-Added Functional Food Ingredients and Nutraceuticals
TL;DR: This review aims to compile recent advances in the science of industrial hemp, with respect to its use as value-added functional food ingredients/nutraceuticals and health benefits, while also highlighting gaps in current knowledge and avenues of future research on this high-value multi-use plant for the global food chain.
194
A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
TL;DR: A narrative review of CBD's applications in human diseases: from mechanism of action to clinical trials.
165
Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Nilo Riva,Gabriele Mora,Gianni Sorarù,Christian Lunetta,Ottavia Eleonora Ferraro,Yuri Falzone,Letizia Leocani,Raffaella Fazio,Mauro Comola,Giancarlo Comi,Fabio Formaglio,Paolo Rossi,Marta Clerici,Yuri Matteo Falzone,Laura Pozzi,Daniele Martinelli,Federica Cerri,Ignazio Diego Lopez,Filippo Martinelli-Boneschi,Angelo Quattrini,Elisabetta Pieri,Kalliopi Marinou,Giorgia Querin,Valeria A. Sansone,Eleonora Maestri,Andrea Calvo,Adriano Chiò +26 more
TL;DR: In this proof-of-concept trial, nabiximols had a positive effect on spasticity symptoms in patients with motor neuron disease and had an acceptable safety and tolerability profile.
85
References
Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.
Mylyne Tham,Orhan Yilmaz,Mariam Alaverdashvili,Melanie E. M. Kelly,Eileen M. Denovan-Wright,Robert B. Laprairie,Robert B. Laprairie +6 more
TL;DR: This work sought to understand why (−)‐cannabidiol (CBD) and (−)-cannABidiol‐dimethylheptyl (C BD‐DMH) exhibit distinct pharmacology, despite near identical structures.
253
Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw
Barbara Costa,Mariapia Colleoni,Silvia Conti,Daniela Parolaro,Chiara Franke,Anna Elisa Trovato,Gabriella Giagnoni +6 more
TL;DR: Oral cannabidiol has a beneficial action on two symptoms of established inflammation: edema and hyperalgesia and the effect on NO seemed to depend on a lower expression of the endothelial isoform of NO synthase.
244
Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis
TL;DR: The data presented here indicate that local administration of CBD blocked OA pain, and suggest that CBD may be a safe, useful therapeutic for treating OA joint neuropathic pain.
A Double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension Using an Oral Mucosal Cannabinoid Extract for Treatment of Chemotherapy-Induced Neuropathic Pain
TL;DR: This pilot trial found a number needed to treat of five and an average decrease of 2.6 on an 11-point NRS-PI in five "responders" and supports that it is worthwhile to study nabiximols in a full randomized, placebo-controlled trial of chemotherapy-induced neuropathic pain.
229
An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With Terminal Cancer-Related Pain Refractory to Strong Opioid Analgesics
TL;DR: Patients who kept using the study medication did not seek to increase their dose of this or other pain-relieving medication over time, suggesting that the adjuvant use of cannabinoids in cancer-related pain could provide useful benefit.
229